Debbie Hasselman

Lundbeck

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research and today our products are available in more than 100 countries. We are tirelessly dedicated to restoring brain health, so every person can be their best.  The neuroscience market is on a growth trajectory. We see rapidly growing knowledge in the field, with many new exciting advances, expanded drugability as well as increased regulatory approvals. Brain disorders are sharply on the increase and the disease burden is growing. We are one of the only global pharmaceutical companies solely focused on the brain, and our research programs tackle some of the most complex challenges in neuroscience. Our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options. We work closely with patients, healthcare professionals and the neuroscience community to uncover causes and to find new treatments that can bring back quality of life to people living with brain disorders. Our ambition is to be #1 in Brain Health in the eyes of the patients we tirelessly serve. We are 5,400 employees in more than 50 countries. We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France, and Italy. Whether we work in labs, at desks or in the field, we are all tirelessly dedicated to restoring brain health. We build on our Danish heritage, fostering a culture of collaboration, responsibility and respect. Too many people worldwide live with brain diseases – complex conditions often invisible to others that nonetheless take a tremendous toll on individuals, families and societies. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions.